Research programme: CCR1 antagonists - Active BiotechAlternative Names: CCR-1 project - Active Biotech
Latest Information Update: 26 Feb 2009
At a glance
- Originator Active Biotech
- Mechanism of Action CCR1 receptor antagonists; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 17 May 2006 Preclinical trials in Autoimmune disorders in Sweden (unspecified route)
- 17 May 2006 Preclinical trials in Inflammation in Sweden (unspecified route)